Bayer's Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

Core Insights - Bayer presented results from the pivotal Phase III OCEANIC-STROKE study, demonstrating the efficacy of its investigational oral Factor XIa inhibitor asundexian [1] Group 1: Study Results - Asundexian (50mg) significantly reduced the incidence of ischemic stroke by 26% compared to placebo, with a confidence interval of 95% (csHR 0.74; 95% CI 0.65–0.84; p) [1]